The FDA has broadened the indication for evolocumab (Repatha; Amgen) to include adults at increased risk of major adverse ...

Jonathan Thompson, MD, MS, explains how financial, insurance, and socioeconomic barriers limit equitable access to biomarker ...

A clinical trial assessing a remote weight loss intervention in women with breast cancer saw a reduction in body weight.

New findings demonstrate an association between increased cumulative depression genetic burden and multiple sclerosis (MS) ...

Clonally expanded CD8+ T cells appear to play a causal role in the initiation and progression of alopecia areata.

Brensocatib, the first FDA-approved dipeptidyl peptidase 1 (DPP1) inhibitor for non–cystic fibrosis bronchiectasis, may have broader potential for other neutrophil-driven conditions, according to ...

Ravi Vij, MD, MBA, explains how insurance-related delays in CAR T approval slow treatment initiation, increase interim therapy costs, and contribute to patient burden.